CORRESP Filing
BriaCell Therapeutics Corp.
Date: April 22, 2025 · CIK: 0001610820 · Accession: 0001641172-25-005685
AI Filing Summary & Sentiment
Reasoning
Letter
ThinkEquity LLC
State Street, 41 st Floor
New York, NY 10004
April 22, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street NE
Washington, D.C. 20549
Attention: Tyler Howes and Jason Drory
Re: BriaCell Therapeutics Corp.
Registration Statement on Form S-1
CIK No. 0001610820
Filed April 22, 2025
Acceleration Request
Requested Date: April 24, 2025
Requested Time: 5:00 pm Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933 , as amended (the " Act "), we, as representative of the underwriters, hereby join in the request of BriaCell Therapeutics Corp. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 5:00 pm, Eastern Time (US), on April 24, 2025, or soon as thereafter practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that the underwriters will distribute as many copies of the Preliminary Prospectus dated April 22, 2025 to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The undersigned, as representatives of the underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very
truly yours,
ThinkEquity
LLC
Show Raw Text
CORRESP 1 filename1.htm ThinkEquity LLC 17 State Street, 41 st Floor New York, NY 10004 April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Tyler Howes and Jason Drory Re: BriaCell Therapeutics Corp. Registration Statement on Form S-1 CIK No. 0001610820 Filed April 22, 2025 Acceleration Request Requested Date: April 24, 2025 Requested Time: 5:00 pm Eastern Time (US) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933 , as amended (the " Act "), we, as representative of the underwriters, hereby join in the request of BriaCell Therapeutics Corp. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 5:00 pm, Eastern Time (US), on April 24, 2025, or soon as thereafter practicable. Pursuant to Rule 460 under the Act, we wish to advise you that the underwriters will distribute as many copies of the Preliminary Prospectus dated April 22, 2025 to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus. The undersigned, as representatives of the underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, ThinkEquity LLC /s/ Eric Lord Eric Lord Head of Investment Banking